MiNK Therapeutics (NASDAQ:INKT – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12), Zacks reports.
MiNK Therapeutics Stock Performance
INKT opened at $8.52 on Tuesday. The company has a market cap of $33.76 million, a PE ratio of -2.18 and a beta of 0.16. The stock has a 50-day moving average of $8.93 and a 200-day moving average of $7.74. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $19.00.
Analyst Upgrades and Downgrades
Separately, HC Wainwright upped their price target on MiNK Therapeutics from $9.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th.
About MiNK Therapeutics
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
See Also
- Five stocks we like better than MiNK Therapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Is Intuitive Machines a Buy After Athena’s Disappointing Landing?
- Stock Sentiment Analysis: How it Works
- Joby Aviation Stock: Virgin Atlantic Deal Signals Big Potential
- The 3 Best Retail Stocks to Shop for in August
- Kohl’s Posts Another Kitchen Sink Quarter, But New CEO Has a Plan
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
